Celine Wilke

3.7k total citations · 2 hit papers
20 papers, 2.2k citations indexed

About

Celine Wilke is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Celine Wilke has authored 20 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 8 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Celine Wilke's work include Advanced Breast Cancer Therapies (7 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Celine Wilke is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Celine Wilke collaborates with scholars based in United States, Switzerland and France. Celine Wilke's co-authors include Fabrice André, Hiroji Iwata, David Mills, Eva Ciruelos, Sibylle Loibl, Mario Campone, Dejan Juric, Hope S. Rugo, Kenichi Inoue and Pierfranco Conté and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Celine Wilke

19 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2019 1.6k citations Fabrice André, Eva Ciruelos et al. New England Journal of Medicine profile →
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

2020 484 citations Robert Zeiser, Nikolas von Bubnoff et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Celine Wilke United States	8	960	905	777	639	407	20	2.2k
Wael A. Harb United States	23	1.4k 1.4×	759 0.8×	923 1.2×	423 0.7×	265 0.7×	118	2.5k
Morten Mau‐Sørensen Denmark	28	1.2k 1.3×	527 0.6×	1.1k 1.4×	541 0.8×	258 0.6×	130	2.7k
John W. Moroney United States	19	874 0.9×	438 0.5×	656 0.8×	493 0.8×	561 1.4×	49	2.5k
Christian Scheffold United States	25	1.0k 1.1×	1.0k 1.1×	900 1.2×	431 0.7×	346 0.9×	75	2.3k
Leslie B. Lee United States	13	790 0.8×	988 1.1×	1.0k 1.3×	325 0.5×	391 1.0×	13	2.3k
James A. Reeves United States	17	1.7k 1.7×	1.4k 1.6×	926 1.2×	351 0.5×	536 1.3×	59	2.6k
Lillian Werner United States	29	823 0.9×	891 1.0×	711 0.9×	499 0.8×	210 0.5×	126	2.4k
Tinya J. Abrams United States	12	835 0.9×	824 0.9×	936 1.2×	322 0.5×	415 1.0×	17	2.1k
Suneel Mundle United States	28	560 0.6×	1.5k 1.7×	913 1.2×	638 1.0×	1.3k 3.2×	131	3.3k
Céline Callens France	27	670 0.7×	480 0.5×	1.0k 1.3×	740 1.2×	197 0.5×	83	2.2k

Countries citing papers authored by Celine Wilke

Since Specialization

Citations

This map shows the geographic impact of Celine Wilke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celine Wilke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celine Wilke more than expected).

Fields of papers citing papers by Celine Wilke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Celine Wilke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celine Wilke. The network helps show where Celine Wilke may publish in the future.

Co-authorship network of co-authors of Celine Wilke

This figure shows the co-authorship network connecting the top 25 collaborators of Celine Wilke. A scholar is included among the top collaborators of Celine Wilke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Celine Wilke. Celine Wilke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Iagaru, Andrei, José Francisco Suárez, Spencer C. Behr, et al.. (2025). Imaging Efficacy of [¹⁸F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study. Journal of Nuclear Medicine. 66(8). 1232–1238.

Herrmann, Ken, Andrei Gafita, Johann S. de Bono, et al.. (2024). Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. EClinicalMedicine. 77. 102862–102862. 8 indexed citations

N., Kim, Andrew J. Armstrong, Bernd J. Krause, et al.. (2024). Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 85(4). 382–391. 17 indexed citations

Herrmann, Ken, Andrei Gafita, Johann S. de Bono, et al.. (2024). Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.. Journal of Clinical Oncology. 42(4_suppl). 208–208. 2 indexed citations

Krause, Bernd J., Kim N., Oliver Sartor, et al.. (2023). Tumor dosimetry of [¹⁷⁷Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study.. Journal of Clinical Oncology. 41(16_suppl). 5046–5046. 4 indexed citations

Herrmann, Ken, Andrei Gafita, Johann S. de Bono, et al.. (2023). Building a predictive model for outcomes with [¹⁷⁷Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results.. Journal of Clinical Oncology. 41(16_suppl). 5028–5028. 4 indexed citations

Socié, Gèrard, Dietger Niederwieser, Nikolas von Bubnoff, et al.. (2023). Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis. Blood. 141(22). 2771–2779. 4 indexed citations

Martelli, Fabrizio, Mario Falchi, Antonio Di Virgilio, et al.. (2022). Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1 mouse model. Experimental Hematology. 117. 43–61. 6 indexed citations

Socié, Gèrard, Dietger Niederwieser, Nikolas von Bubnoff, et al.. (2020). Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study. Blood. 136(Supplement 1). 26–27. 2 indexed citations

10.

Zeiser, Robert, Nikolas von Bubnoff, Jason Butler, et al.. (2020). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. New England Journal of Medicine. 382(19). 1800–1810. 484 indexed citations breakdown →

11.

Perkins, Andrew C., Kate Burbury, Thomas Lehmann, et al.. (2020). Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis. Blood. 136(Supplement 1). 52–53. 9 indexed citations

12.

Martelli, Fabrizio, et al.. (2020). Preclinical Rationale for the Use of Crizanlizumab (SEG101) in Myelofibrosis. Blood. 136(Supplement 1). 26–27. 4 indexed citations

13.

André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 380(20). 1929–1940. 1565 indexed citations breakdown →

14.

Mayer, Ingrid A., Hope S. Rugo, Sibylle Loibl, et al.. (2019). Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1.. Journal of Clinical Oncology. 37(15_suppl). 1039–1039. 3 indexed citations

15.

Juric, Dejan, Sibylle Loibl, Fabrice André, et al.. (2019). Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.. Journal of Clinical Oncology. 37(15_suppl). 1038–1038. 1 indexed citations

16.

Iwata, Hiroji, Toshinari Yamashita, Kenichi Inoue, et al.. (2019). Alpelisib (ALP)+fulvestrant (FUL) in patients from Japan with advanced breast cancer: Subgroup analysis of SOLAR-1 trial. Annals of Oncology. 30. vi80–vi80. 1 indexed citations

17.

Rodón, Jordi, Giuseppe Curigliano, Jean‐Pierre Delord, et al.. (2018). A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 9(60). 31709–31718. 39 indexed citations

18.

Rugo, Hope S., Fabrice André, Gábor Rubovszky, et al.. (2017). A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.. Journal of Clinical Oncology. 35(15_suppl). TPS1111–TPS1111. 5 indexed citations

19.

André, Fabrice, Mario Campone, Eva Ciruelos, et al.. (2016). SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.. Journal of Clinical Oncology. 34(15_suppl). TPS618–TPS618. 14 indexed citations

20.

Baselga, José, Giuseppe Curigliano, Miguel Martín, et al.. (2016). Abstract CT061: A phase Ib study of alpelisib (BYL719) + everolimus ± exemestane in patients with advanced solid tumors or HR+/HER2-breast cancer. Cancer Research. 76(14_Supplement). CT061–CT061. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact